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that its prevalence in immunocompro-
mised Thai children (20%) was higher
than that previously reported in a
healthy Thai population (17.5%) (4)
and in those with recurrent abdominal
pain (11.3%) (5). The prevalence in
children <5 years of age was high
compared with that reported from
Perez-Perez et al. (17.4% vs. 5%) (4).
Although unintentional eradication of
H. pylori after multiple courses of
antimicrobial drugs in such patients
could explain the low prevalence in
some studies, commonly prescribed
antimicrobial drugs without antisecre-
tory agents may be unable to cure the
infection.
The major limitations of this pre-
liminary study were the use of differ-
ent diagnostic methods in the various
studies and the lack of healthy con-
trols. Thus, a well-designed case-con-
trol study is needed. However, the
prevalence of infection with H. pylori
in the immunocompromised children
was high, and these patients appear to
be more susceptible to this infection
in early life. 
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Community Case 
of Methicillin-
resistant
Staphylococcus
aureus Infection
To the Editor: Community-asso-
ciated methicillin-resistant Staphylo-
coccus aureus (CA-MRSA) is an
emerging infectious disease world-
wide and is increasingly reported in
Asia (1). We describe a community
case of invasive MRSA infection,
which appeared as bacteremia and
pneumonia; CA-MRSA was initially
suspected, and eventually the patient
was treated successfully with ampi-
cillin/sulbactam. 
A 52-year-old man with chronic
eczema was admitted to the Prince of
Wales Hospital, Hong Kong, with
fever and chills. Before admission, he
had been treated for infected eczema-
tous lesions for several weeks with
oral ampicillin, cloxacillin, and cefa-
zolin. He had no history of hospital-
ization in the past 10 years, and none
of his family members were health-
care workers. Examination showed an
oral temperature of 40°C, blood pres-
sure 95/55 mm Hg, and no audible
murmur. Cellulitis in the left leg com-
plicated his eczematous skin lesions.
Chest radiograph showed right-mid-
dle-zone pneumonia. Neutrophilia
(leukocytes 15.5 × 109/L, neutrophils
86%), thrombocytopenia (platelets 55
× 109/L), prolonged activated partial
thromboplastin time (43.6 s), and ele-
vated bilirubin level (31 µmol/L)
were observed. Two initial blood cul-
tures grew gram-positive cocci in
clusters, identified as S. aureus by
positive results for catalase and
slide/tube coagulase and a negative
result for ornithine decarboxylase.
Intravenous cloxacillin (2 g every 6 h)
was given on days 2–5. Antimicrobial
drug susceptibility testing was per-
formed by the disk-diffusion method
(1  µg oxacillin/disk, Mueller-Hinton
agar, 2% NaCl), followed by MIC
determination with the agar dilution
method in accordance with NCCLS
(former National Committee for
Clinical Laboratory Standards, now
Clinical and Laboratory Standards
Institute) recommendations (2). One
blood isolate was identified as methi-
cillin-resistant  S. aureus  (MRSA),
with an oxacillin MIC 4 µg/mL. The
other isolate was identified as methi-
cillin-sensitive  S.  aureus (MSSA),
with an oxacillin MIC of 0.5 µg/mL.
In view of a possible CA-MRSA
infection (which could have been β-
lactam–resistant), cloxacillin was sub-
stituted with intravenous vancomycin
plus rifampin on day 5. 
However, the patient’s condition
progressively deteriorated from day 2
to day 10 with persistent fever, chills,
hypotension, and hemoptysis. A
repeated chest radiograph showed
small lung cavities with fluid, and a
thoracic computed tomographic scan
confirmed multiple lung abscesses.
Results of an initial transthoracic
echocardiograph were normal, but a
subsequent transesophageal echocar-
diograph demonstrated tricuspid
valve vegetation.
The MRSA isolate was susceptible
to gentamicin, cotrimoxazole, erythro-
mycin, ciprofloxacin, clindamycin,
fusidic acid, tetracycline, chloram-
phenicol,vancomycin, and rifampin; a
different pattern of multidrug-resistant
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MRSA isolates from that usually
found in our facility (2,3). The isolate
was also susceptible to ampicillin/sul-
bactam, with an equivalent breakpoint
MIC <8/4 µg/mL by disk testing (2).
Latex detection for PBP2a (Slidex
MRSA-Detection, bioMérieux, Marcy
l’Etoile, France) and polymerase
chain reaction (PCR) detection for
mecA were both negative, predicting
nonresistance to oxacillin (2–5). A
nitrocefin-disk test was positive for β-
lactamases, and a 4-fold reduction in
MIC was demonstrated in the pres-
ence of sulbactam (6). Panton-
Valentine leukocidin (PVL) gene
locus was not detected (1).
Community-acquired BORSA (bor-
derline oxacillin-resistant S. aureus),
infective endocarditis, and lung
abscesses were diagnosed. Intra-
venous ampicillin/sulbactam (3 g
every 6 h) was given on day 10 with
rifampin; vancomycin treatment was
stopped. Defervescence occurred 3
days later, subsequent blood cultures
became sterile, and radiographic
changes gradually resolved. Ampi-
cillin/sulbactam was given for 6
weeks without complication. 
As this case suggests, BORSAcan
sometimes be confused with CA-
MRSA because of similar clinical
signs and symptoms and overlapping
oxacillin MICs (2–8 µg/mL and 4–64
µg/mL, respectively) (1,4,6). Both
pathogens can appear as community-
acquired infections and may be relat-
ed to previous antimicrobial drug
usage (6,7). Although CA-MRSA has
been associated with soft tissue infec-
tions and necrotizing pneumonia
(7,8), MSSA or BORSA strains can
also cause these diseases. Thus, in
view of potentially different treat-
ment options, when MRSA isolates
(e.g., oxacillin MICs >4–8  µg/mL)
are associated with community-
acquired, serious infections (e.g.,
blood isolates) and are not multidrug
resistant, one can consider mecA (or
PBP2a) testing to delineate the resist-
ance mechanism (Table). If mecAi s
present, further testing for PVL gene
locus with or without staphylococcal
chromosomal cassette mec (SCCmec)
type IV can be performed to diagnose
CA-MRSA; if mecA is not detected,
further testing for BORSA may be
indicated, and β-lactam therapy
should be evaluated individually. If
these pathogens are not differentiated
and all are treated as CA-MRSA, a
non–β-lactam antimicrobial drug,
such as vancomycin, will be used
(1,4,7,8). However, for serious and
deep-seated S. aureus infections (e.g.,
bacteremia, endocarditis), van-
comycin is inferior to β-lactam
antimicrobial drugs, even when in
vitro testing indicates susceptibility.
Treatment failures have been encoun-
tered (4). Linezolid is a good alterna-
tive but limited by availability and
cost, and clindamycin therapy can be
associated with inducible resistance.
For BORSA-associated infections, β-
lactam antimicrobial drugs, including
high-dose penicillinase-resistant
penicillins (PRPs) (e.g., cloxacillin)
or  β-lactam/β-lactamase–inhibitor
combinations (e.g., ampicillin/sul-
bactam) are regarded as treatments of
choice (4,6,9). 
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BORSA initially described non-
heteroresistant strains of S. aureus
with oxacillin MIC <2 mg/L, which
produce ample β-lactamases and are
rendered fully susceptible to PRP by
β-lactamase-inhibitors (4,6). Sub-
sequent BORSA strains described
have had higher oxacillin MICs (4–8
mg/L) (4). The proportion of BORSA
among clinical isolates of S. aureus
varies (1.4%–12.5%) but is usually
?5% (4,10). A BORSA infection out-
break among dermatology patients
with severe skin diseases has also
been reported (10). Postulated resist-
ance mechanisms include overpro-
duction of conventional penicillinas-
es, production of an inducible, plas-
mid-mediated, membrane-bound
methicillinase, and in some cases,
point mutations of penicillin-binding-
proteins (4). The clinical importance
of BORSA is unknown since early
clinical/animal data suggest treatment
efficacy of PRP (against strains with
MIC <2 mg/L) (4,6,9). Whether
BORSA with higher oxacillin MICs
(4–8 mg/L) will respond equally well
to PRP is less clear. Further studies
into the treatment of BORSA, includ-
ing pharmacokinetic considerations,
are needed (4). However, high-dose
β-lactam/β-lactamase inhibitor com-
binations (e.g., ampicillin/sulbactam),
as shown in animal models, are at
least as effective as PRP (9). In con-
clusion, our report suggests that mecA
(or PBP2a) detection may help man-
age serious, community-acquired,
non–multidrug-resistant MRSAinfec-
tions because of the potential confu-
sion between BORSA and CA-
MRSA. 
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Rickettsia 
massiliae
Human Isolation
To the Editor: The number of new
rickettsial species that cause diseases
in humans is rapidly increasing (1).
Moreover, many of the species first
described in ticks have been recently
shown to be pathogenic. Of the 10
species or subspecies found to be
pathogens after 1984, a total of 7 were
first isolated from ticks (2). We report
the first isolation of Rickettsia massil-
iae from a patient. The bacterium was
isolated in Sicily in 1985 and identi-
fied in 2005.
A 45-year-old man was hospital-
ized in Palermo, Italy, on June 6,
1985, for fever and a rash. He had
been febrile since May 25 and did not
respond to antimicrobial drug treat-
ment using cefamezin, a first-genera-
tion cephalosporin. On examination,
he had a necrotic eschar on his right
ankle, a maculopapular rash on his
palms and soles (online Appendix
Figure 1, available at http://www.cdc.
gov/ncidod/EID/vol12no01/05-0850-
G1.htm), and slight hepatomegaly.
Leukocyte count was normal; he
received tetracyclines for 13 days and
fully recovered. He seroconverted
(from 0 to 1:80 between day 11 and
day 24) by indirect immunofluores-
cence to Rickettsia conorii (R. conorii
spot, bioMérieux, Marcy l’Étoile,
France).
Four milliliters of heparinized
blood sampled before treatment were
inoculated in a 25-cm2 flask contain-
ing Vero cells and incubated at 33°C
in a CO2 incubator (1). Direct
immunofluorescence test on a sample
of the patient’s serum was positive 7
days later. The strain was stored for
20 years and tested in 2005 at the
Unité des Rickettsies for identifica-
tion, and R. massiliae was identified.
DNA was extracted from the cell cul-
ture supernatant and used as template
in 2 previously described polymerase
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